Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.

Challenge

This is the ECCO 2020 poster version of the mesalamine use in CD study (companion to Row 24 ACG 2019 poster). European conference presentation of the finding that oral mesalamine use in CD remained stable despite the 2018 ACG guideline recommending against its use.

Solution

The TARGET-IBD registry was analyzed to track mesalamine prevalence before and after the March 2018 ACG guideline publication, characterizing predictors of continued mesalamine use and the slow penetration of guideline recommendations into real-world practice.

Impact

Presenting the mesalamine guideline non-adherence findings at ECCO 2020 extends the evidence to an international audience, reinforcing the gap between guideline recommendations and real-world CD management practice and strengthening the case for prescriber education initiatives in Crohn's disease.